Castle Biosciences Analyst Ratings
Castle Biosciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/04/2023 | 33.19% | Keybanc | $37 → $25 | Maintains | Overweight |
07/07/2023 | 70.48% | Lake Street | → $32 | Reiterates | Buy → Buy |
07/06/2023 | 97.12% | Stephens & Co. | → $37 | Reiterates | Overweight → Overweight |
06/15/2023 | 59.83% | BTIG | $38 → $30 | Maintains | Buy |
06/07/2023 | 75.81% | Scotiabank | $54 → $33 | Maintains | Sector Outperform |
06/06/2023 | 113.11% | Canaccord Genuity | $60 → $40 | Maintains | Buy |
06/05/2023 | 86.47% | SVB Securities | $50 → $35 | Maintains | Outperform |
06/05/2023 | 70.48% | Lake Street | $41 → $32 | Maintains | Buy |
06/05/2023 | 33.19% | Baird | $35 → $25 | Maintains | Outperform |
05/08/2023 | 118.43% | Stephens & Co. | → $41 | Reiterates | → Overweight |
05/05/2023 | 97.12% | Keybanc | $40 → $37 | Maintains | Overweight |
05/04/2023 | 118.43% | Stephens & Co. | → $41 | Reiterates | → Overweight |
05/04/2023 | 86.47% | Baird | $38 → $35 | Maintains | Outperform |
03/02/2023 | 118.43% | Stephens & Co. | → $41 | Reiterates | → Overweight |
03/01/2023 | 102.45% | Baird | $42 → $38 | Maintains | Outperform |
01/05/2023 | 187.69% | Scotiabank | → $54 | Initiates Coverage On | → Sector Outperform |
11/03/2022 | 118.43% | Baird | $48 → $41 | Maintains | Outperform |
08/09/2022 | 155.73% | Baird | $44 → $48 | Maintains | Outperform |
08/09/2022 | 166.38% | SVB Leerink | $45 → $50 | Maintains | Market Outperform |
05/11/2022 | 113.11% | Keybanc | $90 → $40 | Maintains | Overweight |
05/10/2022 | 134.42% | Baird | $50 → $44 | Maintains | Outperform |
05/10/2022 | 139.74% | SVB Leerink | $65 → $45 | Maintains | Outperform |
04/05/2022 | 326.21% | Canaccord Genuity | $94 → $80 | Maintains | Buy |
03/01/2022 | 235.64% | Lake Street | $94 → $63 | Maintains | Buy |
01/07/2022 | 214.33% | Stephens & Co. | → $59 | Initiates Coverage On | → Overweight |
11/09/2021 | 299.57% | SVB Leerink | $85 → $75 | Maintains | Outperform |
07/14/2021 | 352.85% | SVB Leerink | $80 → $85 | Maintains | Outperform |
04/30/2021 | 400.8% | Lake Street | → $94 | Initiates Coverage On | → Buy |
02/03/2021 | 379.49% | Keybanc | $70 → $90 | Maintains | Overweight |
01/15/2021 | 326.21% | SVB Leerink | $70 → $80 | Maintains | Outperform |
12/11/2020 | 272.94% | SVB Leerink | $57 → $70 | Maintains | Outperform |
11/10/2020 | 272.94% | Keybanc | → $70 | Initiates Coverage On | → Overweight |
09/25/2020 | 203.68% | SVB Leerink | $50 → $57 | Maintains | Outperform |
08/11/2020 | 166.38% | SVB Leerink | $45 → $50 | Maintains | Outperform |
05/12/2020 | 139.74% | SVB Leerink | $40 → $45 | Maintains | Outperform |
03/27/2020 | 86.47% | Baird | $38 → $35 | Maintains | Outperform |
03/11/2020 | 102.45% | Baird | $37 → $38 | Maintains | Outperform |
12/27/2019 | 86.47% | Canaccord Genuity | $34 → $35 | Maintains | Buy |
09/04/2019 | 65.16% | Baird | $27 → $31 | Maintains | Outperform |
09/04/2019 | 81.14% | Canaccord Genuity | $26 → $34 | Maintains | Buy |
08/19/2019 | 33.19% | BTIG | → $25 | Initiates Coverage On | → Buy |
08/19/2019 | 38.52% | Canaccord Genuity | → $26 | Initiates Coverage On | → Buy |
08/19/2019 | 49.17% | SVB Leerink | → $28 | Initiates Coverage On | → Outperform |
08/19/2019 | 43.85% | Baird | → $27 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
08/04/2023 | 33.19% | Keybanc | 37 美元 → 25 美元 | 維護 | 超重 |
07/07/2023 | 70.48% | 湖街 | → 32 美元 | 重申 | 購買 → 購買 |
07/06/2023 | 97.12% | Stephens & Co. | → 37 美元 | 重申 | 超重 → 超重 |
06/15/2023 | 59.83% | BTIG | 38 美元 → 30 美元 | 維護 | 購買 |
06/07/2023 | 75.81% | 豐業銀行 | 54 美元 → 33 美元 | 維護 | 板塊表現跑贏大盤 |
06/06/2023 | 113.11% | Canaccord Genu | 60 美元 → 40 美元 | 維護 | 購買 |
06/05/2023 | 86.47% | SVB 證券 | 50 美元 → 35 美元 | 維護 | 跑贏大盤 |
06/05/2023 | 70.48% | 湖街 | 41 美元 → 32 美元 | 維護 | 購買 |
06/05/2023 | 33.19% | 貝爾德 | 35 美元 → 25 美元 | 維護 | 跑贏大盤 |
05/08/2023 | 118.43% | Stephens & Co. | → 41 美元 | 重申 | → 超重 |
05/05/2023 | 97.12% | Keybanc | 40 美元 → 37 美元 | 維護 | 超重 |
05/04/2023 | 118.43% | Stephens & Co. | → 41 美元 | 重申 | → 超重 |
05/04/2023 | 86.47% | 貝爾德 | 38 美元 → 35 美元 | 維護 | 跑贏大盤 |
03/02/2023 | 118.43% | Stephens & Co. | → 41 美元 | 重申 | → 超重 |
03/01/2023 | 102.45% | 貝爾德 | 42 美元 → 38 美元 | 維護 | 跑贏大盤 |
01/05/2023 | 187.69% | 豐業銀行 | → 54 美元 | 啓動覆蓋開啓 | → 板塊表現跑贏大盤 |
11/03/2022 | 118.43% | 貝爾德 | 48 美元 → 41 美元 | 維護 | 跑贏大盤 |
08/09/2022 | 155.73% | 貝爾德 | 44 美元 → 48 美元 | 維護 | 跑贏大盤 |
08/09/2022 | 166.38% | SVB Leerink | 45 美元 → 50 美元 | 維護 | 市場表現跑贏大盤 |
05/11/2022 | 113.11% | Keybanc | 90 美元 → 40 美元 | 維護 | 超重 |
05/10/2022 | 134.42% | 貝爾德 | 50 美元 → 44 美元 | 維護 | 跑贏大盤 |
05/10/2022 | 139.74% | SVB Leerink | 65 美元 → 45 美元 | 維護 | 跑贏大盤 |
2022 年 5 月 4 日 | 326.21% | Canaccord Genu | 94 美元 → 80 美元 | 維護 | 購買 |
03/01/2022 | 235.64% | 湖街 | 94 美元 → 63 美元 | 維護 | 購買 |
2022 年 7 月 1 日 | 214.33% | Stephens & Co. | → 59 美元 | 啓動覆蓋開啓 | → 超重 |
2021 年 9 月 11 日 | 299.57% | SVB Leerink | 85 美元 → 75 美元 | 維護 | 跑贏大盤 |
2021 年 7 月 14 日 | 352.85% | SVB Leerink | 80 美元 → 85 美元 | 維護 | 跑贏大盤 |
2021 年 4 月 30 日 | 400.8% | 湖街 | → 94 美元 | 啓動覆蓋開啓 | → 購買 |
02/03/2021 | 379.49% | Keybanc | 70 美元 → 90 美元 | 維護 | 超重 |
2021 年 1 月 15 日 | 326.21% | SVB Leerink | 70 美元 → 80 美元 | 維護 | 跑贏大盤 |
2020 年 11 月 12 日 | 272.94% | SVB Leerink | 57 美元 → 70 美元 | 維護 | 跑贏大盤 |
11/10/2020 | 272.94% | Keybanc | → 70 美元 | 啓動覆蓋開啓 | → 超重 |
2020 年 9 月 25 日 | 203.68% | SVB Leerink | 50 美元 → 57 美元 | 維護 | 跑贏大盤 |
08/11/2020 | 166.38% | SVB Leerink | 45 美元 → 50 美元 | 維護 | 跑贏大盤 |
05/12/2020 | 139.74% | SVB Leerink | 40 美元 → 45 美元 | 維護 | 跑贏大盤 |
2020 年 3 月 27 日 | 86.47% | 貝爾德 | 38 美元 → 35 美元 | 維護 | 跑贏大盤 |
03/11/2020 | 102.45% | 貝爾德 | 37 美元 → 38 美元 | 維護 | 跑贏大盤 |
12/27/2019 | 86.47% | Canaccord Genu | 34 美元 → 35 美元 | 維護 | 購買 |
09/04/2019 | 65.16% | 貝爾德 | 27 美元 → 31 美元 | 維護 | 跑贏大盤 |
09/04/2019 | 81.14% | Canaccord Genu | 26 美元 → 34 美元 | 維護 | 購買 |
08/19/2019 | 33.19% | BTIG | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
08/19/2019 | 38.52% | Canaccord Genu | → 26 美元 | 啓動覆蓋開啓 | → 購買 |
08/19/2019 | 49.17% | SVB Leerink | → 28 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
08/19/2019 | 43.85% | 貝爾德 | → 27 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
What is the target price for Castle Biosciences (CSTL)?
Castle Biosciences(CSTL)的目標價格是多少?
The latest price target for Castle Biosciences (NASDAQ: CSTL) was reported by Keybanc on August 4, 2023. The analyst firm set a price target for $25.00 expecting CSTL to rise to within 12 months (a possible 33.19% upside). 19 analyst firms have reported ratings in the last year.
Keybanc於2023年8月4日公佈了Castle Biosciences(納斯達克股票代碼:CSTL)的最新目標股價。這家分析公司將目標股價定爲25.00美元,預計CSTL將在12個月內升至12個月內(可能上漲33.19%)。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Castle Biosciences (CSTL)?
Castle Biosciences(CSTL)的最新分析師評級是多少?
The latest analyst rating for Castle Biosciences (NASDAQ: CSTL) was provided by Keybanc, and Castle Biosciences maintained their overweight rating.
Castle Biosciences(納斯達克股票代碼:CSTL)的最新分析師評級由Keybanc提供,Castle Biosciences維持其增持評級。
When is the next analyst rating going to be posted or updated for Castle Biosciences (CSTL)?
Castle Biosciences(CSTL)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Castle Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Castle Biosciences was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Castle Biosciences的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。Castle Biosciences的最後一次評級是在2023年8月4日提交的,因此你應該預計下一個評級將在2024年8月4日左右公佈。
Is the Analyst Rating Castle Biosciences (CSTL) correct?
分析師對 Castle Biosciences (CSTL) 的評級正確嗎?
While ratings are subjective and will change, the latest Castle Biosciences (CSTL) rating was a maintained with a price target of $37.00 to $25.00. The current price Castle Biosciences (CSTL) is trading at is $18.77, which is out of the analyst's predicted range.
儘管評級是主觀的,將會發生變化,但最新的Castle Biosciences(CSTL)評級維持不變,目標股價爲37.00美元至25.00美元。Castle Biosciences(CSTL)目前的交易價格爲18.77美元,超出了分析師的預測區間。